NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

TRK抑制劑:現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析)

TRK Inhibitors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024219
出版日期 內容資訊 英文 236 Pages
商品交期: 3-5個工作天內
價格
TRK抑制劑:現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析) TRK Inhibitors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 236 Pages
簡介

本報告提供TRK抑制劑市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,各市場區隔的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 TRK抑制劑的概要與流行病學研究

第4章 TRK抑制劑的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 TRK抑制劑的交易趨勢

第7章 TRK抑制劑開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH1902

GervanoRA's pipeline analysis and opportunity assessment report "TRK Inhibitors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed TRK Inhibitors pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry.

The report has been divided into segments like TRK Inhibitors Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the TRK Inhibitors historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current TRK Inhibitors Market (2020) and the Forecasted TRK Inhibitors Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of TRK Inhibitors Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the TRK Inhibitors Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of TRK Inhibitors Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: TRK INHIBITORS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: TRK INHIBITORS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF TRK INHIBITORS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF TRK INHIBITORS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: MARKET RESEARCH DATA ON APPROVED TRK INHIBITOR DRUGS (USD)
  • TABLE 03: ESTIMATED AVERAGE SELLING PRICES OF FILED AND LATE-CLINICAL STAGE TRK TARGETED PIPELINE DRUGS
  • TABLE 04: PERCEIVED VALUE OF TRK INHIBITORS PRESCRIPTION DRUG BY COMPETITIVE BENCHMARKING
  • TABLE 05: FINANCING DEALS IN TRK INHIBITOR THERAPEUTIC AREA
  • TABLE 06: LICENSING DEALS
  • TABLE 07: MERGER AND ACQUISITION DEALS
  • TABLE 08: COLLABORATION DEALS
  • TABLE 09: TRK INHIBITORS PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 10: PRE-REGISTRATION STAGE PIPELINE DRUGS
  • TABLE 11: PHASE III PIPELINE DRUGS
  • TABLE 12: PHASE II PIPELINE DRUGS
  • TABLE 13: TRK INHIBITOR PHASE I PIPELINE MOLECULES
  • TABLE 14: TRK INHIBITOR PRE-CLINICAL PIPELINE MOLECULES
  • TABLE 15: TERMINATED TRK INHIBITORS PIPELINE MOLECULES
  • TABLE 16: PIPELINE DRUGS ALONG WITH ANTICIPATED REGION OF APPROVAL
  • TABLE 17: CLINICAL STAGE PIPELINE DRUGS WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 18: PIPELINE DRUGS WITH THEIR MOLECULAR TARGET RECEPTORS
  • TABLE 19: PIPELINE DRUGS WITH THEIR TARGETED INDICATIONS
  • TABLE 20: TRK TARGETED PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE TRK BASED THERAPIES COMPETITIVE SPACE
  • FIGURE 02: FORECASTED ANNUAL INCREASE IN TRK INHIBITORS DRUG MARKET
  • FIGURE 03: TRK INHIBITORS TOTAL MARKET SHARE
  • FIGURE 04: COMPARISON OF TRK INHIBITORS MARKET TARGETING NTRK FUSION CANCERS & OTHER INDICATIONS
  • FIGURE 05: COMPARISON OF ESTIMATED SALES FOR THE KEY LATE CLINICAL STAGE DRUGS
  • FIGURE 06: COMPARISON OF EXPECTED PEAK SALES OF SITRAVATINIB AND REPOTRECTINIB
  • FIGURE 07: ESTIMATED MARKET SHARE OF TRK INHIBITORS TARGETING NTRK GENE FUSION POSITIVE CANCERS IN 2029
  • FIGURE 08: TRK INHIBITORS DRUG PIPELINE SCENARIO, DRUG CANDIDATES VS HSD AND COMPANY TYPE
  • FIGURE 09: SHARE OF PREVALENCE OF THREE MAJOR CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 10: SHARE OF PREVALENCE OF OTHER CANCERS WITH NTRK GENE FUSIONS - WORLDWIDE
  • FIGURE 11: ESTIMATED PATIENT POPULATION ELIGIBLE FOR TREATMENT WITH TRK INHIBITORS
  • FIGURE 12: TOTAL ESTIMATED TARGET POPULATION SHARE WITH NTRK GENE FUSION POSITIVE CANCERS IN 2020
  • FIGURE 13: TOTAL REALIZED MARKET SHARE AND UNREALIZED MARKET SHARE IN 2020
  • FIGURE 14: TOTAL TARGET POPULATION ELIGIBLE TO RECEIVE TRK INHIBITORS IN 2020 AND 2029
  • FIGURE 15: ESTIMATED TARGET POPULATION FOR TRK INHIBITORS IN THE YEAR 2029